With the help of patient groups, biotechs hone in on rare diseases
The approach it takes to drugs is focused on turning off specific disease-causing genes, and it has one drug in development for cancers and another for a rare form of hyperoxaluria (too much oxylate in the urine). "It's the best application of our ...
Boston Business Journal (blog) - Thu, 26 Feb 2015 11:23

Dicerna Pharmaceuticals Announces Move to Larger Office and Lab Space in ...
In 2015, Dicerna will start clinical development of a second innovative medicine, DCR-PH1, which has the potential to be a functional cure for the serious and difficult-to-treat genetic disease primary hyperoxaluria type 1 (PH1). Dicerna is currently ...
Business Wire (press release) - Thu, 26 Feb 2015 04:22

Alnylam Aims to Release Multi-program Clinical Data in 1H 2015
The company, which also posted its fourth quarter 2014 financial results, further disclosed that it aims to begin human studies for its hepatic porphyria treatment ALN-AS1 and to select a development candidate for its program in primary hyperoxaluria ...
GenomeWeb - Fri, 13 Feb 2015 06:24

Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q4 2014 Results ...
Seeking Alpha (registration) - Thu, 12 Feb 2015 20:15

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial ...
Business Wire (press release) - Thu, 12 Feb 2015 13:00

Allena Pharmaceuticals Secures $25 Million Series B Financing
“The positive response and level of interest we have received from investors is a great reflection of our seasoned management team, the market opportunity and the unmet need that ALLN-177 meets in the treatment of hyperoxaluria,” said Alexey Margolin, ...
Business Wire (press release) - Thu, 04 Dec 2014 04:00

Biotech partners at Allena fund a march toward PhIII with $25M venture round
FierceBiotech - Thu, 04 Dec 2014 05:53

Poster Highlights Rapid and Durable Effect of DCR-PH1 in Mouse Model of PH1
WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, presented data from its preclinical program in primary hyperoxaluria type 1 (PH1) in a poster session at the ...
Business Wire (press release) - Tue, 14 Oct 2014 14:22

A London experience 1995-2012: Demographic, dietary and biochemical ...
The prevalence of low urine volume, hypercalciuria, hyperoxaluria, hyperuricosuria and hypocitraturia was 5.6%, 38%, 7.9%, 18% and 23%, respectively. The prevalence of several risk factors for stones increased over time. The majority of stones were ...
UroToday - Thu, 26 Feb 2015 18:17

Researchers Demonstrate Promise of Dicerna Investigational Therapy in ...
... Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced the presentation of preclinical data demonstrating the promise of DCR-PH1, the Company's therapeutic candidate for the treatment of primary hyperoxaluria ...
Business Wire (press release) - Mon, 30 Jun 2014 05:00

Why Dicerna Pharmaceuticals Inc Stock Skyrocketed
Motley Fool - Mon, 30 Jun 2014 14:01

The Latest Discovery by Dicerna Pharmaceuticals (NASDAQ:DRNA)
Stocks.org - Tue, 01 Jul 2014 20:33

Dicerna Pharmaceuticals Flying After Positive Pre-Clinical Data On PH1
Bidness Etc - Mon, 30 Jun 2014 12:07

OxThera Initiates Clinical Trial in Primary Hyperoxaluria
OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that it has initiated a clinical study in in Primary Hyperoxaluria. This announcement bolsters the Company's position as a leader in developing therapies for ...
PR Newswire (press release) - Wed, 08 Jan 2014 00:31


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014